

Gyula Szegedi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11617266/publications.pdf>

Version: 2024-02-01

54
papers

2,085
citations

257450

24
h-index

233421

45
g-index

57
all docs

57
docs citations

57
times ranked

2517
citing authors

#	ARTICLE	IF	CITATIONS
1	Impaired endothelial function in patients with undifferentiated connective tissue disease: a follow-up study. <i>Rheumatology</i> , 2014, 53, 2035-2043.	1.9	12
2	Increased levels of anti-heat-shock protein 60 (anti-Hsp60) indicate endothelial dysfunction, atherosclerosis and cardiovascular diseases in patients with mixed connective tissue disease. <i>Immunologic Research</i> , 2014, 60, 50-59.	2.9	12
3	Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders. <i>Human Immunology</i> , 2013, 74, 1510-1518.	2.4	38
4	Clinical Course, Prognosis, and Causes of Death in Mixed Connective Tissue Disease. <i>Journal of Rheumatology</i> , 2013, 40, 1134-1142.	2.0	85
5	Associations entre lâ€™Ã©pitope partagÃ© de lâ€™HLA, les anticorps anti-peptide citrullinÃ© et les facteurs liÃ©s au mode de vie chez des patients hongrois atteints de polyarthrite rhumatoÃ©de: donnÃ©es de la premiÃ¨re cohorte de lâ€™Europe centrale et de lâ€™est. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2012, 79, 93-94.	0.0	0
6	Associations of HLA-shared epitope, anti-citrullinated peptide antibodies and lifestyle-related factors in Hungarian patients with rheumatoid arthritis: Data from the first Central-Eastern European cohort. <i>Joint Bone Spine</i> , 2011, 78, 652-653.	1.6	7
7	Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. <i>Autoimmunity Reviews</i> , 2011, 10, 155-162.	5.8	48
8	Vitamin D insufficiency in a large MCTD population. <i>Autoimmunity Reviews</i> , 2011, 10, 317-324.	5.8	50
9	Comparative assessment of vascular function in autoimmune rheumatic diseases: Considerations of prevention and treatment. <i>Autoimmunity Reviews</i> , 2011, 10, 416-425.	5.8	98
10	Assessment of Subclinical Vascular Disease Associated with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 723-729.	2.0	96
11	New classification of the shared epitope in rheumatoid arthritis: impact on the production of various anti-citrullinated protein antibodies. <i>Rheumatology</i> , 2010, 49, 25-33.	1.9	28
12	Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease. <i>Arthritis Research and Therapy</i> , 2010, 12, R78.	3.5	30
13	Oxidized LDL induces <i>in vitro</i> lymphocyte activation in antiphospholipid syndrome. <i>Autoimmunity</i> , 2010, 43, 334-339.	2.6	8
14	Anti-nucleosome antibody, a reliable indicator for lupus nephritis. <i>Autoimmunity</i> , 2009, 42, 393-398.	2.6	27
15	Sensorineural Hearing Loss in Patients with Mixed Connective Tissue Disease: Immunological Markers and Cytokine Levels. <i>Journal of Rheumatology</i> , 2009, 36, 1930-1936.	2.0	24
16	Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2009, 28, 705-710.	2.2	115
17	A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. <i>Clinical Rheumatology</i> , 2009, 28, 655-662.	2.2	91
18	Plasma Homocysteine Levels, The Prevalence of Methylenetetrahydrofolate Reductase Gene C677T Polymorphism and Macrovascular Disorders in Systemic Sclerosis: Risk Factors for Accelerated Macrovascular Damage?. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 145-149.	6.5	27

#	ARTICLE	IF	CITATIONS
19	Vitamin D deficiency in undifferentiated connective tissue disease. <i>Arthritis Research and Therapy</i> , 2008, 10, R123.	3.5	106
20	Progressive divergent shifts in natural and induced T-regulatory cells signify the transition from undifferentiated to definitive connective tissue disease. <i>International Immunology</i> , 2008, 20, 971-979.	4.0	25
21	Evaluation of paraoxonase activity in patients with mixed connective tissue disease. <i>Journal of Rheumatology</i> , 2008, 35, 237-43.	2.0	14
22	Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. <i>Journal of Rheumatology</i> , 2008, 35, 398-406.	2.0	130
23	Gene expression profiles of systemic lupus erythematosus and rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 797-806.	3.0	4
24	Analysis of Components of the CD14/TLR System on Leukocytes of Patients with Atopic Dermatitis. <i>International Archives of Allergy and Immunology</i> , 2007, 143, 177-184.	2.1	11
25	Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2007, 98, 413-419.	3.4	22
26	Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2007, 6, 497-502.	5.8	75
27	Reduced Paraoxonase1 Activity Is a Risk for Atherosclerosis in Patients with Systemic Lupus Erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 83-91.	3.8	54
28	Accelerated Atherosclerosis in Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 349-358.	3.8	94
29	Association of HELLP syndrome with primary antiphospholipid syndrome—a case report. <i>Clinical Rheumatology</i> , 2007, 27, 111-113.	2.2	10
30	Clinical Thrombotic Manifestations in SLE Patients With and Without Antiphospholipid Antibodies: A 5-year Follow-up. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 131-137.	6.5	44
31	Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1658-63.	2.0	52
32	Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. <i>Journal of Autoimmunity</i> , 2006, 27, 211-217.	6.5	75
33	Diastolic function of the heart in mixed connective tissue disease. <i>Clinical Rheumatology</i> , 2006, 26, 176-181.	2.2	15
34	Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with iloprost. <i>Rheumatology International</i> , 2006, 26, 264-269.	3.0	23
35	Association of Rheumatoid Arthritis with HLA-DR1 and HLA-DR4 in Hungary. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 263-270.	3.8	39
36	Soluble complement receptor 1 (CD35) bound to immune complexes in sera of patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 52, 2950-2951.	6.7	5

#	ARTICLE	IF	CITATIONS
37	Long-Term Survival of Patients With Idiopathic Inflammatory Myopathies According to Clinical Features. <i>Medicine (United States)</i> , 2004, 83, 35-42.	1.0	267
38	Plasmapheresis Modulates TH1/TH2 Imbalance in Patients with Systemic Lupus Erythematosus According to Measurement of Intracytoplasmic Cytokines. <i>Autoimmunity</i> , 2002, 35, 51-56.	2.6	24
39	A novel flow cytometric assay to quantify soluble CD14 concentration in human serum. <i>Cytometry</i> , 2001, 45, 115-123.	1.8	8
40	High frequency of t(14;18) translocation in Sjögren's syndrome: Comment on the article by Gellrich et al. <i>Arthritis and Rheumatism</i> , 2000, 43, 951.	6.7	1
41	Retrospective evaluation of 5-fluorouracil-interferon- β treatment of advanced colorectal cancer patients. <i>Pathology and Oncology Research</i> , 2000, 6, 175-178.	1.9	0
42	Catastrophic antiphospholipid syndrome in cancer. <i>Haematologia</i> , 2000, 30, 303-311.	0.3	20
43	Different effects of an oligonucleotide uptake stimulating protein on leukemic cells in their primitive and differentiated state. <i>FEBS Letters</i> , 1998, 430, 241-245.	2.8	2
44	Plasma Endothelin Correlates With Antiendothelial Antibodies in Patients With Mixed Connective Tissue Disease. <i>Circulation</i> , 1995, 92, 2969-2974.	1.6	44
45	Anticytoskeletal antibodies in systemic autoimmune diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1994, 3, 31-35.	2.4	0
46	Marker profile, enzyme activity, and function of a human myelomonocytic leukemia cell line. <i>Cellular Immunology</i> , 1992, 139, 531-540.	3.0	17
47	Immunogenetic and immunologic studies of differentiated thyroid cancer. <i>Cancer</i> , 1989, 63, 1318-1326.	4.1	36
48	Antigen density on the surface of mononuclear cells in SLE. <i>Immunology Letters</i> , 1987, 15, 243-247.	2.5	4
49	Acid phosphatase activity in monocytes and sera of patients with Hodgkin's disease. <i>Cancer Letters</i> , 1986, 32, 219-222.	7.2	2
50	Subset specificity of lupus antilymphocyte antibodies studied by two-colour microfluorimetry. <i>Immunology Letters</i> , 1985, 10, 91-93.	2.5	4
51	Monocyte activation in patients with Hodgkin's disease. <i>International Journal of Cancer</i> , 1984, 34, 483-485.	5.1	5
52	Studies on the lymphocyte subpopulation in systemic lupus erythematosus by monoclonal antibodies. <i>Immunology Letters</i> , 1983, 7, 57-60.	2.5	2
53	Enzyme-linked immunosorbent assay for antibodies to native DNA in sera of patients with SLE. <i>Journal of Immunological Methods</i> , 1982, 48, 169-175.	1.4	37
54	Suppressor activity of peripheral blood mononuclear cells in patients with chronic discoid lupus erythematosus. <i>Archives of Dermatological Research</i> , 1979, 265, 317-320.	1.9	3